BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 14750321)

  • 1. [Phase I study of gemcitabine (GEM) and UFT combination chemotherapy for unresectable/recurrent pancreatic cancer].
    Nakamori S; Tujie M; Takahashi Y; Maruhashi S; Miyamoto A; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
    Gan To Kagaku Ryoho; 2004 Jan; 31(1):51-4. PubMed ID: 14750321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Phase I/II study of combination chemotherapy with gemcitabine and UFT for advanced pancreatic cancer in a multi-center trial].
    Sumii T; Funakoshi A; Mizumoto K; Tanaka M; Arita Y; Ito T; Yamaguchi H; Ueki T; Sakai T; Miyahara T; Muranaka T; Igarashi H; Shinozaki H; Eriguchi N
    Gan To Kagaku Ryoho; 2008 Apr; 35(4):603-6. PubMed ID: 18408428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of oral uracil-tegafur prior to weekly intravenous gemcitabine in patients with advanced pancreatic cancer.
    Tanno S; Nakano Y; Osanai M; Koizumi K; Izawa T; Habiro A; Mizukami Y; Yanagawa N; Fujii T; Okumura T; Kohgo Y
    Chemotherapy; 2006; 52(2):98-102. PubMed ID: 16567941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study on low dose gemcitabine plus oral chemotherapy with uracil-tegafur and cyclophosphamide in combination with radiotherapy against recurrent and advanced pancreatic cancer.
    Nio Y; Hashimoto K; Yano S; Itakura M; Koike M; Yamaguchi K; Endo S; Tsuji M; Higami T; Maruyama R
    Oncol Rep; 2005 Aug; 14(2):401-8. PubMed ID: 16012722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Multicenter phase II study of pre-administered uracil/tegafur (UFT) plus gemcitabine for unresectable/recurrent pancreatic cancer].
    Nakamori S; Endo W; Ozato H; Shibata T; Takeda Y; Tohno K; Hasuike Y; Masutani S; Morimoto T; Doki Y; Mori M; Monden M
    Gan To Kagaku Ryoho; 2011 May; 38(5):789-92. PubMed ID: 21566438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A case of recurrent pancreatic cancer responding to TS-1 combined gemcitabine chemotherapy after UFT combined gemcitabine chemotherapy resulting progressive disease].
    Sunagozaka H; Yamashita T; Kagaya T; Kato Y; Kaneko S
    Gan To Kagaku Ryoho; 2006 Jun; 33(6):829-32. PubMed ID: 16770107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Gemcitabine in combination with S-1 or UFT in patients with advanced pancreatic cancer].
    Sasajima J; Tanno S; Koizumi K; Nakano Y; Habiro A; Chiba A; Fujii T; Sugiyama Y; Nakamura K; Nishikawa T; Mizukami Y; Okumura T; Kohgo Y
    Gan To Kagaku Ryoho; 2009 Oct; 36(10):1657-61. PubMed ID: 19838023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients.
    Morizane C; Okusaka T; Ueno H; Kondo S; Ikeda M; Furuse J; Shinichi O; Nakachi K; Mitsunaga S; Kojima Y; Suzuki E; Ueno M; Yamaguchi T
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):957-64. PubMed ID: 22120961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer.
    Yoshitomi H; Togawa A; Kimura F; Ito H; Shimizu H; Yoshidome H; Otsuka M; Kato A; Nozawa S; Furukawa K; Miyazaki M;
    Cancer; 2008 Nov; 113(9):2448-56. PubMed ID: 18823024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer.
    Lee J; Park JO; Kim WS; Lee SI; Song SY; Lim DH; Choi SH; Heo JS; Lee KT; Lee JK; Kim K; Jung CW; Im YH; Lee MH; Kang WK; Park K
    Oncology; 2004; 66(1):32-7. PubMed ID: 15031596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer.
    Oh DY; Cha Y; Choi IS; Yoon SY; Choi IK; Kim JH; Oh SC; Kim CD; Kim JS; Bang YJ; Kim YH
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):527-36. PubMed ID: 19578850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas.
    Feliu J; Mel R; Borrega P; López Gómez L; Escudero P; Dorta J; Castro J; Vázquez-Estévez SE; Bolaños M; Espinosa E; González Barón M;
    Ann Oncol; 2002 Nov; 13(11):1756-62. PubMed ID: 12419748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of gemcitabine, UFT and leucovorin in patients with advanced pancreatic cancer.
    Kim TW; Kang HJ; Ahn JH; Lee K; Chang HM; Kang YK; Lee JS
    Acta Oncol; 2002; 41(7-8):689-94. PubMed ID: 14651215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Phase I study of gemcitabine (GEM) and docetaxel (TXT) combination chemotherapy for unresectable non-small-cell lung cancer].
    Terao I
    Gan To Kagaku Ryoho; 2002 Nov; 29(11):1929-33. PubMed ID: 12465392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.
    Mackay HJ; Hill M; Twelves C; Glasspool R; Price T; Campbell S; Massey A; Macham MA; Uzzel M; Bailey SM; Martin C; Cunningham D
    Ann Oncol; 2003 Aug; 14(8):1264-9. PubMed ID: 12881390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of oral uracil and Tegafur plus leucovorin and pelvic radiation in patients with recurrent rectal cancer.
    Schiebe ME; Reese T; Wenz F; Schmidberger H; Engenhart-Cabillic R; Dunst J; Hess CF; Hoffmann W
    Anticancer Drugs; 2002 Nov; 13(10):1005-9. PubMed ID: 12439334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 14-day schedule.
    Pazdur R; Lassere Y; Diaz-Canton E; Bready B; Ho DH
    Invest New Drugs; 1997; 15(2):123-8. PubMed ID: 9220291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
    Arima S; Shimizu K; Okamoto T; Toki M; Suzuki Y; Okano N; Naruge D; Kawai K; Kobayashi T; Kasuga A; Kitamura H; Takasu A; Nagashima F; Sugiyama M; Furuse J
    Anticancer Res; 2017 Feb; 37(2):909-914. PubMed ID: 28179351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of combined UFT plus leucovorin and radiotherapy for pancreatic cancer.
    Childs HA; Spencer SA; Raben D; Bonner JA; Newsome J; Robert F
    Int J Radiat Oncol Biol Phys; 2000 Jul; 47(4):939-44. PubMed ID: 10863063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer.
    Lee KW; Kim YJ; Lee KH; Han SW; Kim TY; Oh DY; Im SA; Kim TY; Bang YJ; Choi IS; Kim JH
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):447-55. PubMed ID: 24947909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.